AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors

被引：0
|
作者：
Dowlati, A. [1 ]
Richardson, D. L. [2 ]
Lorusso, P. [3 ]
Spira, A. I. [4 ]
Bashir, B. [5 ]
Hirmand, M. [6 ]
Mehta, M. [6 ]
Patel, M. R. [7 ]
机构：
[1] Case Western Reserve Univ, Div Hematol & Oncol, Dept Med, Cleveland, OH USA
[2] Univ Oklahoma, Gynecol Oncol Sect, Dept Obstet & Gynecol Sect Gynecol Oncol, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Yale Univ, Dept Med Oncol, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT USA
[4] Virginia Canc Specialists, VCS Res Inst, Fairfax, VA USA
[5] Thomas Jefferson Univ, Div Solid Tumors, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA USA
[6] Avenzo Therapeut Inc, Clin Dev, San Diego, CA USA
[7] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
439TiP
引用
收藏
页码：S405 / S405
页数：1
相关论文
共 50 条
  • [21] Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors
    Angevin, Eric
    Elez, Elena
    Cohen, Steven J.
    Van Laethem, Jean-Luc
    Ottensmeier, Christian
    Joly, Florence
    Ray-Coquard, Isabelle
    Lopez-Martin, Jose A.
    Dirix, Luc
    Machiels, Jean-Pascal
    Clive, Sally
    Steven, Neil Matthew
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas
    Bandekar, Rajesh
    Van de Velde, Helgi
    Tromp, Brenda J.
    Vermeulen, Jessica
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
    Altan, M.
    Patnaik, A.
    Barve, M. A.
    Dunn, L.
    Cobb, P. W.
    Rosenberg, A.
    Sharma, S.
    Sukari, A.
    Lee, Z.
    Marcondes, M. Q.
    Zalevsky, J.
    Tagliaferri, M. A.
    Kotzin, B.
    Sacco, A. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S860 - S861
  • [23] A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
    Yun, T.
    Shin, S. J.
    Kim, D-W.
    Yun, C. H.
    Heo, S.
    Hyun, B.
    Kim, Y. S.
    Kim, J. S.
    Moon, Y. W.
    ANNALS OF ONCOLOGY, 2022, 33 : S20 - S20
  • [24] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [25] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [26] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Olszanski, Anthony J.
    Desai, Madhuri
    Jansen, Mendel
    Scheyer, Richard David
    Senaldi, Giorgio
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] A Phase 1, First-in- human, Multicentre, Open-label, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumors
    Ulaner, Gary
    Juloori, Aditya
    Juneau, Daniel
    Schindler, Joanne
    Allan, Stephanie
    Jean-Louis, Lisa
    Nawinne, Moditha
    Mueller, Nancy
    Littlewood, Gillian
    Trigg, William
    Jacene, Heather
    Iagaru, Andrei
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [28] A phase I/IIa, first time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
    Blackman, Samuel C.
    Gainer, Shelby D.
    Suttle, Benjamin B.
    Skordos, Konstantine W.
    Greshock, Joel D.
    Motwani, Monica
    Roadcap, Lori T.
    Hardwicke, Mary Ann A.
    Wooster, Richard F.
    CANCER RESEARCH, 2012, 72
  • [29] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
12345